Healthy Prognosis for Diagnostic and Imaging Companies
This article was originally published in Start Up
Executive Summary
Investors in diagnostics and imaging companies are watching the values of their stakes rise following strong IPOs.
You may also be interested in...
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007
Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007
Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
Diagnostic Imaging: Screening Faces Scrutiny
At the 2007 annual meeting of the Radiological Society of North America in November, the sparkle of new innovations was tarnished somewhat by questions about the rapid proliferation of advanced imaging technologies and their cost effectiveness. As a result both new and old technologies are facing an uphill battle to prove their worth in a heavily scrutinized economic environment.